The Manufacture of Xeno‐ and Feeder‐Free Clinical‐Grade Human Embryonic Stem Cell Lines: First Step for Cell Therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F22%3A00076402" target="_blank" >RIV/00159816:_____/22:00076402 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/22:00076402 RIV/00216224:14110/22:00126955

Výsledek na webu

<a href="https://www.mdpi.com/1422-0067/23/20/12500" target="_blank" >https://www.mdpi.com/1422-0067/23/20/12500</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/ijms232012500" target="_blank" >10.3390/ijms232012500</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The Manufacture of Xeno‐ and Feeder‐Free Clinical‐Grade Human Embryonic Stem Cell Lines: First Step for Cell Therapy

Popis výsledku v původním jazyce

Human embryonic stem cells (hESCs) are increasingly used in clinical trials as they can change the outcome of treatment for many human diseases. They are used as a starting material for further differentiation into specific cell types and to achieve the desirable result of the cell therapy; thus, the quality of hESCs has to be taken into account. Therefore, current good manufacturing prac- tice (cGMP) has to be implemented in the transport of embryos, derivation of inner cell mass to xeno-free, feeder-free and defined hESC culture, and cell freezing. The in-depth characterization of hESC lines focused on safety, pluripotency, differentiation potential and genetic background has to complement this process. In this paper, we show the derivation of three clinical-grade hESC lines, MUCG01, MUCG02, and MUCG03, following these criteria. We developed and validated the sys- tem for the manufacture of xeno-free and feeder-free clinical-grade hESC lines that present high- quality starting material suitable for cell therapy according to cGMP.

Název v anglickém jazyce

The Manufacture of Xeno‐ and Feeder‐Free Clinical‐Grade Human Embryonic Stem Cell Lines: First Step for Cell Therapy

Popis výsledku anglicky

Human embryonic stem cells (hESCs) are increasingly used in clinical trials as they can change the outcome of treatment for many human diseases. They are used as a starting material for further differentiation into specific cell types and to achieve the desirable result of the cell therapy; thus, the quality of hESCs has to be taken into account. Therefore, current good manufacturing prac- tice (cGMP) has to be implemented in the transport of embryos, derivation of inner cell mass to xeno-free, feeder-free and defined hESC culture, and cell freezing. The in-depth characterization of hESC lines focused on safety, pluripotency, differentiation potential and genetic background has to complement this process. In this paper, we show the derivation of three clinical-grade hESC lines, MUCG01, MUCG02, and MUCG03, following these criteria. We developed and validated the sys- tem for the manufacture of xeno-free and feeder-free clinical-grade hESC lines that present high- quality starting material suitable for cell therapy according to cGMP.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Molecular Sciences

ISSN

1422-0067

e-ISSN

1422-0067

Svazek periodika

23

Číslo periodika v rámci svazku

20

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

15

Strana od-do

12500

Kód UT WoS článku

000874331900001

EID výsledku v databázi Scopus

2-s2.0-85140991806